1[1]Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, and advanced generation 8 - met hoxy fluoroquinolone . J Respir Dis, 1999;20:70 ～ 76
2[2]Lipsky BA, Baker GA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis, 1999;28:352 ～ 354
3[3]Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am, 2000 ; 84 :1447 ～ 1464
4[4]Blum MD, Graham DJ, McClosky GA. Temafloxacin syndrome: Review of 95 cases. Clin Infect Dis, 1994; 18: 946 ～ 950
5[5]Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother, 1990;26(Suppl D) :31 ～ 34
6[6]Steffen R, Jori R, Dupont HL, et al. Efficacy and toxicity of fleroxacin in the treatment of travelers' diarrhea. Am J Med, 1993;94(Suppl 3A) :182～ 186
7[7]Kimura N, Miyazaki E, Matsuno O, et al. Drug - induced pneumonitis with eosinophilic imfiltration due to tosufloxacin tosilate. Nihon Kokyuki Gakka;Zasshi, 1998;36:618 ～ 622
8[8]Segev S, Yaniv I, Haverstock D, et al. Safety of long- term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review. Clin Infect Dis, 1999;28:299 ～ 308
8KI-IURAD A M, MAHULIKAR A, RATHOD M K,et al. Vertical transmission of Nuclear Polyhedrosis Virus in the silkworm, Bombyx mori L [J]. Invertebrate Pathology,2004(87):8-15.
